Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience

M. Spunarova, N. Tom, S. Pavlova, M. Mraz, Y. Brychtova, M. Doubek, A. Panovska, H. Skuhrova Francova, A. Brzobohata, S. Pospisilova, J. Mayer, M. Trbusek,

. 2019 ; 81 (-) : 75-81. [pub] 20190425

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20023915

Grantová podpora
NV16-32743A MZ0 CEP - Centrální evidence projektů

The impact of genetic aberrations on rituximab-based therapeutic regimens has been intensely studied in chronic lymphocytic leukemia (CLL). According to the current consensus chemoimmunotherapy consisting of rituximab and DNA-damaging drugs is not suitable for patients with TP53 defects. In our study, we focused on CLL patients with an intact TP53 gene and investigated four recurrently mutated genes in CLL, genomic aberrations by FISH, and IGHV status with the aim of analyzing their impact on progression-free survival (PFS) after front-line therapy with FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) regimens. Using next-generation sequencing, we analyzed 120 patients treated with FCR and 57 patients treated with BR at a university hospital. We used a 10% cut-off for variant allele frequency and recorded the following mutation frequencies in the pre-therapy samples: ATM 23%, SF3B1 20%, NOTCH1 19% and BIRC3 11%. The data on cytogenetic aberrations (11q22, 13q14, trisomy 12) and IGHV mutation status were also considered in PFS analyses. In univariate analyses, we observed a negative impact of BIRC3 mutations and 11q22 deletion in both regimens, while the unmutated IGHV status was associated with a significantly shorter PFS only in the FCR-treated cohort. In a multivariate analysis, only deletion 11q22 in both regimens, and the unmutated IGHV in the FCR cohort maintained an independent association with the reduced PFS. Notably, sole 11q22 deletion, without an ATM mutation on the other allele, manifested the shortest PFS of all analyzed markers. Deletion 11q22 and IGHV status predict PFS in previously untreated CLL patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20023915
003      
CZ-PrNML
005      
20201214131701.0
007      
ta
008      
201125s2019 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.leukres.2019.04.015 $2 doi
035    __
$a (PubMed)31054420
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Spunarova, Michaela $u Dept. of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Jihlavska 20, 625 00, Brno, Czech Republic.
245    10
$a Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience / $c M. Spunarova, N. Tom, S. Pavlova, M. Mraz, Y. Brychtova, M. Doubek, A. Panovska, H. Skuhrova Francova, A. Brzobohata, S. Pospisilova, J. Mayer, M. Trbusek,
520    9_
$a The impact of genetic aberrations on rituximab-based therapeutic regimens has been intensely studied in chronic lymphocytic leukemia (CLL). According to the current consensus chemoimmunotherapy consisting of rituximab and DNA-damaging drugs is not suitable for patients with TP53 defects. In our study, we focused on CLL patients with an intact TP53 gene and investigated four recurrently mutated genes in CLL, genomic aberrations by FISH, and IGHV status with the aim of analyzing their impact on progression-free survival (PFS) after front-line therapy with FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) regimens. Using next-generation sequencing, we analyzed 120 patients treated with FCR and 57 patients treated with BR at a university hospital. We used a 10% cut-off for variant allele frequency and recorded the following mutation frequencies in the pre-therapy samples: ATM 23%, SF3B1 20%, NOTCH1 19% and BIRC3 11%. The data on cytogenetic aberrations (11q22, 13q14, trisomy 12) and IGHV mutation status were also considered in PFS analyses. In univariate analyses, we observed a negative impact of BIRC3 mutations and 11q22 deletion in both regimens, while the unmutated IGHV status was associated with a significantly shorter PFS only in the FCR-treated cohort. In a multivariate analysis, only deletion 11q22 in both regimens, and the unmutated IGHV in the FCR cohort maintained an independent association with the reduced PFS. Notably, sole 11q22 deletion, without an ATM mutation on the other allele, manifested the shortest PFS of all analyzed markers. Deletion 11q22 and IGHV status predict PFS in previously untreated CLL patients.
650    _2
$a senioři $7 D000368
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a bendamustin hydrochlorid $x aplikace a dávkování $7 D000069461
650    _2
$a nádorové biomarkery $x genetika $7 D014408
650    12
$a chromozomální aberace $7 D002869
650    _2
$a lidské chromozomy, pár 11 $x genetika $7 D002880
650    _2
$a kohortové studie $7 D015331
650    _2
$a cyklofosfamid $x aplikace a dávkování $7 D003520
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a těžké řetězce imunoglobulinů $x genetika $7 D007143
650    _2
$a variabilní oblast imunoglobulinu $x genetika $7 D007135
650    _2
$a imunoterapie $x metody $7 D007167
650    _2
$a chronická lymfatická leukemie $x farmakoterapie $x genetika $x imunologie $x mortalita $7 D015451
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a mutace $7 D009154
650    _2
$a prognóza $7 D011379
650    _2
$a rituximab $x aplikace a dávkování $7 D000069283
650    _2
$a míra přežití $7 D015996
650    _2
$a vidarabin $x aplikace a dávkování $x analogy a deriváty $7 D014740
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Tom, Nikola $u Dept. of Molecular Medicine, Central European Institute of Technology (CEITEC), Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic.
700    1_
$a Pavlova, Sarka $u Dept. of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Jihlavska 20, 625 00, Brno, Czech Republic; Dept. of Molecular Medicine, Central European Institute of Technology (CEITEC), Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic.
700    1_
$a Mraz, Marek $u Dept. of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Jihlavska 20, 625 00, Brno, Czech Republic; Dept. of Molecular Medicine, Central European Institute of Technology (CEITEC), Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic.
700    1_
$a Brychtova, Yvona $u Dept. of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Jihlavska 20, 625 00, Brno, Czech Republic.
700    1_
$a Doubek, Michael $u Dept. of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Jihlavska 20, 625 00, Brno, Czech Republic; Dept. of Molecular Medicine, Central European Institute of Technology (CEITEC), Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic.
700    1_
$a Panovska, Anna $u Dept. of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Jihlavska 20, 625 00, Brno, Czech Republic.
700    1_
$a Skuhrova Francova, Hana $u Dept. of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Jihlavska 20, 625 00, Brno, Czech Republic.
700    1_
$a Brzobohata, Anna $u Dept. of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Jihlavska 20, 625 00, Brno, Czech Republic.
700    1_
$a Pospisilova, Sarka $u Dept. of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Jihlavska 20, 625 00, Brno, Czech Republic; Dept. of Molecular Medicine, Central European Institute of Technology (CEITEC), Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic.
700    1_
$a Mayer, Jiri $u Dept. of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Jihlavska 20, 625 00, Brno, Czech Republic; Dept. of Molecular Medicine, Central European Institute of Technology (CEITEC), Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic.
700    1_
$a Trbusek, Martin $u Dept. of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Jihlavska 20, 625 00, Brno, Czech Republic. Electronic address: Trbusek.Martin@fnbrno.cz.
773    0_
$w MED00003141 $t Leukemia research $x 1873-5835 $g Roč. 81, č. - (2019), s. 75-81
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31054420 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214131658 $b ABA008
999    __
$a ok $b bmc $g 1596234 $s 1114591
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 81 $c - $d 75-81 $e 20190425 $i 1873-5835 $m Leukemia research $n Leuk Res $x MED00003141
GRA    __
$a NV16-32743A $p MZ0
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...